October 10, 2024 10:40 PM EDT
R&D

Sanofi dis­con­tin­ues De­nali-part­nered MS tri­al af­ter Phase 2 fail­ure

Max Bayer

Pharma Reporter

Sanofi is end­ing a Phase 2 clin­i­cal tri­al that’s test­ing a drug from De­nali for mul­ti­ple scle­ro­sis, end­ing the de­vel­op­ment plan.

De­nali said in

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Eli Lil­ly inks an­oth­er obe­si­ty pact, dou­bling down on small Swiss part­ner

Sev­en pa­tients di­ag­nosed with blood can­cer af­ter Skysona treat­ment, new da­ta show

Star­board launch­es first sal­vo in Pfiz­er fight, al­leg­ing ex-CEO, CFO were pres­sured to flip

Im­mat­ics heads to Phase 3 with melanoma cell ther­a­py, seeks to raise $150M

A service from the Financial Times